The characteristic mutational signature of the BRCA1/2 variant carrier cancer, homologous recombination deficiency28, makes the cancers responsive to platinum-based therapy or PARP-inhibitors29,30, but most of the carriers are still treated according to standard indications31. Here, BRCA1 is linked to cancer.